Liquid biopsies have begun to incorporate analyses of epigenetic modification for screening purposes to detect cancer-derived DNA in the blood. Additionally, epigenetic modifications are being used to assign a tissue of origin to the cancer to direct confirmatory diagnostic procedures.
Obtaining sufficient amounts of ccfDNA for assay development validation, and proficiency testing is difficult. Furthermore, methods of analyzing the epigenetic modifications, such as bisulfite conversion, can damage a significant fraction of the input material; but, failing to carry the methods to completion can result in an over-estimation of methylation.
This poster from LGC SeraCare presents data on three reference materials created to address challenges associated with assessing the methylation of circulating cell-free DNA in order to support the design, optimization, and validation of liquid biopsies for detecting cancer-derived DNA in the blood.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences